|
|
术前评分模型预测减瘤结局在晚期卵巢癌中的研究现状
|
Abstract:
晚期卵巢癌治疗的标准方案为初始肿瘤细胞减灭术，术后补充以铂类为基础的联合化疗，近年来新的一种治疗方案应用愈加广泛，即行新辅助化疗后再行中间型肿瘤细胞减灭术。制定治疗方案前，须由妇科肿瘤医师基于实现满意减瘤的可能性和患者机体状况进行详细评估。目前有很多研究提出了术前评分模型以判断晚期卵巢癌患者接受初次肿瘤细胞减灭术的可能性，旨在实现满意减瘤结局、不影响生存预后的同时尽量降低手术并发症发生率，包括主要评估盆腹腔播散程度的腹膜癌指数和Eisenkop评分、评估手术复杂程度的手术复杂性评分、术前经腹腔镜探查评估肿瘤负荷的Fagotii腹腔镜评分和相应的术后并发症评分系统、以术前CT为基础的Suidan评分、预测R0切除可能的R0评分，以及结合多种评分模型的综合预测模型。
The standard treatment for advanced ovarian cancer is primary debulking surgery followed by platinum-based combination chemotherapy. In recent years, a new treatment approach has become increasingly popular, which involves neoadjuvant chemotherapy followed by interval debulking surgery. Before formulating a treatment plan, a detailed assessment is necessary, based on the possibility of achieving satisfactory cytoreduction and the patient’s overall condition. Currently, many studies have proposed preoperative scoring models to predict the possibility of primary cytoreductive surgery for advanced ovarian cancer patients, aiming to achieve satisfactory cytoreduction outcomes without affecting survival prognosis while minimizing the incidence of surgical complications. These models include the peritoneal cancer index and Eisenkop score for evaluating the extent of pelvic and abdominal dissemination, the surgical complexity score for assessing the complexity of the surgery, the Fagotii laparoscopic score and the corresponding postoperative complication scoring system for evaluating tumor burden through preoperative laparoscopy, the Suidan score based on preoperative CT, the R0 score for predicting the possibility of R0 resection, and comprehensive predictive models combining multiple scoring systems.
| [1] | 郑荣寿, 陈茹, 韩冰峰, 王少明, 李荔, 孙可欣. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. |
| [2] | González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., et al. (2023) Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Annals of Oncology, 34, 833-848. https://doi.org/10.1016/j.annonc.2023.07.011 |
| [3] | Onda, T., Satoh, T., Ogawa, G., Saito, T., Kasamatsu, T., Nakanishi, T., et al. (2020) Comparison of Survival between Primary Debulking Surgery and Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers in Phase III Randomised Trial. European Journal of Cancer, 130, 114-125. https://doi.org/10.1016/j.ejca.2020.02.020 |
| [4] | Fagotti, A., Ferrandina, M.G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., et al. (2020) Randomized Trial of Primary Debulking Surgery versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPI-ON-NCT01461850). International Journal of Gynecological Cancer, 30, 1657-1664. https://doi.org/10.1136/ijgc-2020-001640 |
| [5] | Kehoe, S., Hook, J., Nankivell, M., Jayson, G.C., Kitchener, H., Lopes, T., et al. (2015) Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. https://doi.org/10.1016/s0140-6736(14)62223-6 |
| [6] | Vergote, I., Tropé, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., et al. (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine, 363, 943-953. https://doi.org/10.1056/nejmoa0908806 |
| [7] | Horner, W., Peng, K., Pleasant, V., Brackmann, M., Ebott, J., Gutfreund, R., et al. (2019) Trends in Surgical Complexity and Treatment Modalities Utilized in the Management of Ovarian Cancer in an Era of Neoadjuvant Chemotherapy. Gynecologic Oncology, 154, 283-289. https://doi.org/10.1016/j.ygyno.2019.05.023 |
| [8] | Harmon, R.L. and Sugarbaker, P.H. (2005) Prognostic Indicators in Peritoneal Carcinomatosis from Gastrointestinal Cancer. International Seminars in Surgical Oncology, 2, Article No. 3. https://doi.org/10.1186/1477-7800-2-3 |
| [9] | Asp, M., Malander, S., Bengtsson, J., Sartor, H. and Kannisto, P. (2022) Prognostic Value of Peritoneal Cancer Index after Complete Cytoreductive Surgery in Advanced Ovarian Cancer. Anticancer Research, 42, 2541-2551. https://doi.org/10.21873/anticanres.15732 |
| [10] | Sanson, C., Roosen, A., Faron, M., Zaccarini, F., Maulard, A., Scherier, S., et al. (2024) Correlation between Peritoneal Cancer Index and Survival in Advanced Epithelial Ovarian Cancer with Complete Resection. International Journal of Gynecological Cancer, 34, 730-737. https://doi.org/10.1136/ijgc-2023-005158 |
| [11] | Aletti, G.D., Dowdy, S.C., Podratz, K.C. and Cliby, W.A. (2007) Relationship among Surgical Complexity, Short-Term Morbidity, and Overall Survival in Primary Surgery for Advanced Ovarian Cancer. American Journal of Obstetrics and Gynecology, 197, 676.e1-676.e7. https://doi.org/10.1016/j.ajog.2007.10.495 |
| [12] | Aletti, G.D., Eisenhauer, E.L., Santillan, A., Axtell, A., Aletti, G., Holschneider, C., et al. (2011) Identification of Patient Groups at Highest Risk from Traditional Approach to Ovarian Cancer Treatment. Gynecologic Oncology, 120, 23-28. https://doi.org/10.1016/j.ygyno.2010.09.010 |
| [13] | Eisenkop, S.M., Spirtos, N.M., Friedman, R.L., Lin, W.M., Pisani, A.L. and Perticucci, S. (2003) Relative Influences of Tumor Volume before Surgery and the Cytoreductive Outcome on Survival for Patients with Advanced Ovarian Cancer: A Prospective Study. Gynecologic Oncology, 90, 390-396. https://doi.org/10.1016/s0090-8258(03)00278-6 |
| [14] | du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I. and Pfisterer, J. (2009) Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer, 115, 1234-1244. https://doi.org/10.1002/cncr.24149 |
| [15] | Harter, P., Sehouli, J., Lorusso, D., Reuss, A., Vergote, I., Marth, C., et al. (2019) A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. New England Journal of Medicine, 380, 822-832. https://doi.org/10.1056/nejmoa1808424 |
| [16] | Fagotti, A., Ferrandina, G., Fanfani, F., Ercoli, A., Lorusso, D., Rossi, M., et al. (2006) A Laparoscopy-Based Score to Predict Surgical Outcome in Patients with Advanced Ovarian Carcinoma: A Pilot Study. Annals of Surgical Oncology, 13, 1156-1161. https://doi.org/10.1245/aso.2006.08.021 |
| [17] | Fagotti, A., Vizzielli, G., De Iaco, P., Surico, D., Buda, A., Mandato, V.D., et al. (2013) A Multicentric Trial (Olympia-Mito 13) on the Accuracy of Laparoscopy to Assess Peritoneal Spread in Ovarian Cancer. American Journal of Obstetrics and Gynecology, 209, 462.e1-462.e11. https://doi.org/10.1016/j.ajog.2013.07.016 |
| [18] | Tang, X., Zhang, X., Liu, X., Zheng, T., Hua, K. and Qiu, J. (2021) A Novel Laparoscopy-Based Model for the Prediction of Optimal Cytoreduction and Prognosis of Epithelial Ovarian Cancer in a Chinese Population. European Journal of Obstetrics & Gynecology and Reproductive Biology, 256, 256-262. https://doi.org/10.1016/j.ejogrb.2020.11.028 |
| [19] | Saner, F.A.M., Ruggeri, G., Siegenthaler, F., Wampfler, J., Imboden, S. and Mueller, M.D. (2023) Change of Fagotti Score Is Associated with Outcome after Neoadjuvant Chemotherapy for Ovarian Cancer. International Journal of Gynecological Cancer, 33, 1595-1601. https://doi.org/10.1136/ijgc-2023-004540 |
| [20] | Vizzielli, G., Costantini, B., Tortorella, L., Pitruzzella, I., Gallotta, V., Fanfani, F., et al. (2016) A Laparoscopic Risk-Adjusted Model to Predict Major Complications after Primary Debulking Surgery in Ovarian Cancer: A Single-Institution Assessment. Gynecologic Oncology, 142, 19-24. https://doi.org/10.1016/j.ygyno.2016.04.020 |
| [21] | Strong, V.E., Selby, L.V., Sovel, M., Disa, J.J., Hoskins, W., Dematteo, R., et al. (2014) Development and Assessment of Memorial Sloan Kettering Cancer Center’s Surgical Secondary Events Grading System. Annals of Surgical Oncology, 22, 1061-1067. https://doi.org/10.1245/s10434-014-4141-4 |
| [22] | Suidan, R.S., Ramirez, P.T., Sarasohn, D.M., Teitcher, J.B., Iyer, R.B., Zhou, Q., et al. (2017) A Multicenter Assessment of the Ability of Preoperative Computed Tomography Scan and CA-125 to Predict Gross Residual Disease at Primary Debulking for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 145, 27-31. https://doi.org/10.1016/j.ygyno.2017.02.020 |
| [23] | Gu, B., Xia, L., Ge, H. and Liu, S. (2020) Preoperative PET/CT Score Can Predict Complete Resection in Advanced Epithelial Ovarian Cancer: A Prospective Study. Quantitative Imaging in Medicine and Surgery, 10, 743-753. https://doi.org/10.21037/qims.2020.02.19 |
| [24] | Feng, Z., Wen, H., Jiang, Z., Liu, S., Ju, X., Chen, X., et al. (2018) A Triage Strategy in Advanced Ovarian Cancer Management Based on Multiple Predictive Models for R0 Resection: A Prospective Cohort Study. Journal of Gynecologic Oncology, 29, e65. https://doi.org/10.3802/jgo.2018.29.e65 |
| [25] | Dessapt, A., Huchon, C., Ngo, C., Bats, A., Bensaid, C. and Lecuru, F. (2016) Is Complete Cytoreductive Surgery Feasible in This Patient with Ovarian Cancer? Surgical Oncology, 25, 326-331. https://doi.org/10.1016/j.suronc.2016.07.001 |
| [26] | Piedimonte, S., Bernardini, M.Q., Ding, A., Laframboise, S., Ferguson, S.E., Bouchard-Fortier, G., et al. (2022) Integrated Prediction Model of Patient Factors, Resectability Scores and Surgical Complexity to Predict Cytoreductive Outcome and Guide Treatment Plan in Advanced Ovarian Cancer. Gynecologic Oncology, 166, 453-459. https://doi.org/10.1016/j.ygyno.2022.06.026 |
| [27] | Straubhar, A.M., Wolf, J.L., Zhou, M.Q.C., Iasonos, A., Cham, S., Wright, J.D., et al. (2021) Advanced Ovarian Cancer and Cytoreductive Surgery: Independent Validation of a Risk-Calculator for Perioperative Adverse Events. Gynecologic Oncology, 160, 438-444. https://doi.org/10.1016/j.ygyno.2020.11.021 |
